ERBB2 and breast carcinoma: An increased breast cancer risk in current versus never-users of MHT for the ER+/PR+/HER2- subtype has been reported in the Nurses’ Health Study and California Teachers’ Cohort Study and from a Norwegian screening program nested case-control study [29,37,38].